Zhang Qimin, Huang Shengsong, Luo Huarong, Zhao Xin, Wu Gang, Wu Denglong
Department of Urology, Tongji Hospital, Tongji UniversityShanghai 200065, China.
Am J Cancer Res. 2017 Apr 1;7(4):935-945. eCollection 2017.
Bladder cancer is one of the most prevalent cancers worldwide, and increasing research has focused on new technologies for early detection of bladder cancer. For example, proteomic techniques for biomarker discovery have been implemented for the detection and analysis of protein changes in the tissues, blood, and urine from bladder cancer patients. In this present study, we evaluated the effectiveness of the eight-plex iTRAQ labeling and quantitative proteomic approaches for differentially analyzing proteins found in normal and bladder cancer tissues from individual patients. This study obtained 1627 identified and quantified proteins, and detected significant changes of expression in 35 proteins. In addition, both mass spectrometry and Western Blot results indicated that scaffold attachment factor B (SafB) and GTPase RAN binding protein 1 (RanBP1) were up-regulated in low-grade bladder cancer tissues. Overall, this study suggests that these two proteins are potential candidates as predictive and diagnostic biomarkers and that they may be potentially used as the therapeutic targets for drug discovery.
膀胱癌是全球最常见的癌症之一，越来越多的研究聚焦于膀胱癌早期检测的新技术。例如，用于发现生物标志物的蛋白质组学技术已被用于检测和分析膀胱癌患者组织、血液和尿液中的蛋白质变化。在本研究中，我们评估了八重iTRAQ标记和定量蛋白质组学方法对个体患者正常组织和癌组织中差异蛋白质进行分析的有效性。本研究共鉴定和定量了1627种蛋白质，检测到35种蛋白质的表达有显著变化。此外，质谱和蛋白质印迹结果均表明，支架附着因子B（SafB）和GTP酶RAN结合蛋白1（RanBP1）在低级别膀胱癌组织中上调。总体而言，本研究表明这两种蛋白质是作为预测和诊断生物标志物的潜在候选物，并且它们可能潜在地用作药物发现的治疗靶点。
